JAN 05, 2017
Timely Access to Compounded Ophthalmic Treatments at Risk Due to New FDA Requirements
The FDA is moving forward with a proposal to bar traditional, 503A compounding pharmacies from distributing compounded drugs without a patient-specific prescription.